# Eating Behavior Changes on Five Obesity Drugs: A 66-Patient Brazilian Study

A Brazilian study mapped eating-behavior changes across five obesity medications, including hedonic eating dz 2.06 on tirzepatide, in 66 early responders who had lost 5% by three months.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/sixty-six-people-and-a-heatmap
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Eating Behavior Changes on Five Obesity Drugs: A 66-Patient Brazilian Study

A Brazilian clinic scored five eating-behavior domains before and after six months on five obesity medications. The effect sizes are large, and the analyzed cohort was 66 early responders.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Selected within-group effect sizes (Cohen’s dᶻ) · Tirzepatide, pleasure-driven eating · 2.06 · Naltrexone/bupropion, emotional eating · 2.04 · Semaglutide, emotional eating · 1.52 · 66 early responders across five medication groups

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   The study followed 66 adults who had lost at least 5% of their weight by month three.
-   Participants reported changes in eating behavior after six months on one of five medications.
-   The study could not tell whether eating patterns predict which medication will work best.

A São Paulo team measured changes in five eating behaviors after six months of treatment (n = 66) [\[1\]](https://buythisglp.com/research/sixty-six-people-and-a-heatmap#ref-1). The scale asked about habits such as eating for pleasure or in response to emotion. That differs from [studies on intrusive thoughts about food](https://buythisglp.com/research/do-glp1-drugs-reduce-food-noise), which look at how often thoughts about eating occupy someone’s attention. Both approaches rely on what participants report.

## What changed in the questionnaire?

The largest reported reduction in pleasure-driven eating was in the tirzepatide group (Cohen’s dᶻ = 2.06). The reported change in emotional eating was 2.04 in the naltrexone/bupropion group and 1.52 in the semaglutide group [\[1\]](https://buythisglp.com/research/sixty-six-people-and-a-heatmap#ref-1). These are standardized changes within each treatment group. They are neither percentages nor estimates of how much better one medication worked than another.

Everyone had already responded to treatment

The analysis included people with complete baseline and six-month assessments who had lost at least 5% of their starting weight by month three. That selection leaves out people who lost less and those without complete follow-up [\[1\]](https://buythisglp.com/research/sixty-six-people-and-a-heatmap#ref-1).

## Can the scores guide treatment selection?

The study was retrospective, with no randomized assignment or untreated group. Research on [why weight loss varies on GLP-1 treatment](https://buythisglp.com/research/why-do-some-people-not-lose-weight-on-a-glp1) puts this cohort in context. The study could describe how early responders’ ratings changed, but it could not predict response from a person’s starting score.

## Frequently asked

Can a drug be matched to my eating pattern?

Not on this evidence. The idea is reasonable, but this study analyzed 66 people across five medications with no control group, which is far too little to guide a choice.

Why are the effect sizes so large?

They are standardized changes from baseline within each group. The small groups and lack of randomization make those estimates unsuitable for comparing medications.

Who was included?

Only early responders — people who had already lost at least 5% of their weight at three months — so the findings describe people for whom treatment was already working.

## Sources

1.  \[1\] Pineda-Wieselberg RJ, Soares AH, Napoli TF, Scalissi NM, Salles JEN (2026). Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice Nutrients. [PMID 42124020](https://pubmed.ncbi.nlm.nih.gov/42124020/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
